Tc Biopharm Plc Stock Performance
| TCBPW Stock | USD 0.01 0 6.25% |
TC BioPharm holds a performance score of 6 on a scale of zero to a hundred. The firm owns a Beta (Systematic Risk) of 3.01, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, TC BioPharm will likely underperform. Use TC BioPharm plc standard deviation and the relationship between the value at risk and market facilitation index , to analyze future returns on TC BioPharm plc.
Risk-Adjusted Performance
6 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in TC BioPharm plc are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, TC BioPharm showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:50 | Last Split Date 2022-11-21 |
1 | TC BioPharm denies Nasdaq delisting rumors - Investing.com | 10/25/2024 |
2 | ARMISTICE CAPITAL, LLC Acquires New Stake in TC BioPharm Holdin - GuruFocus.com | 11/15/2024 |
| Begin Period Cash Flow | 4.8 M | |
| Free Cash Flow | -10.7 M |
TCBPW |
TC BioPharm Relative Risk vs. Return Landscape
If you would invest 2.90 in TC BioPharm plc on August 31, 2024 and sell it today you would lose (1.40) from holding TC BioPharm plc or give up 48.28% of portfolio value over 90 days. TC BioPharm plc is currently producing 2.0865% returns and takes up 26.0042% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than TCBPW, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
TC BioPharm Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for TC BioPharm's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as TC BioPharm plc, and traders can use it to determine the average amount a TC BioPharm's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0802
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | TCBPW | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 26.0 actual daily | 96 96% of assets are less volatile |
Expected Return
| 2.09 actual daily | 41 59% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 6 94% of assets perform better |
Based on monthly moving average TC BioPharm is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of TC BioPharm by adding it to a well-diversified portfolio.
TC BioPharm Fundamentals Growth
TCBPW Stock prices reflect investors' perceptions of the future prospects and financial health of TC BioPharm, and TC BioPharm fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on TCBPW Stock performance.
| Return On Equity | -12.17 | ||||
| Return On Asset | -1.09 | ||||
| EBITDA | (13.61 M) | ||||
| Net Income | (5.91 M) | ||||
| Cash And Equivalents | 1.55 M | ||||
| Cash Per Share | 0.08 X | ||||
| Total Debt | 1.8 M | ||||
| Current Ratio | 0.18 X | ||||
| Book Value Per Share | 3.38 X | ||||
| Cash Flow From Operations | (10.54 M) | ||||
| Earnings Per Share | (0.75) X | ||||
| Total Asset | 8.93 M | ||||
| Retained Earnings | (38.84 M) | ||||
| Working Capital | 950.33 K | ||||
About TC BioPharm Performance
Evaluating TC BioPharm's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if TC BioPharm has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if TC BioPharm has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.71) | (0.75) | |
| Return On Capital Employed | (3.41) | (3.58) | |
| Return On Assets | (0.66) | (0.69) | |
| Return On Equity | (2.20) | (2.09) |
Things to note about TC BioPharm plc performance evaluation
Checking the ongoing alerts about TC BioPharm for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for TC BioPharm plc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| TC BioPharm plc is way too risky over 90 days horizon | |
| TC BioPharm plc has some characteristics of a very speculative penny stock | |
| TC BioPharm plc appears to be risky and price may revert if volatility continues | |
| TC BioPharm plc has high likelihood to experience some financial distress in the next 2 years | |
| TC BioPharm plc has accumulated 1.8 M in total debt. TC BioPharm plc has a current ratio of 0.18, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Note, when we think about TC BioPharm's use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (5.91 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| TC BioPharm plc has accumulated about 1.55 M in cash with (10.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from news.google.com: ARMISTICE CAPITAL, LLC Acquires New Stake in TC BioPharm Holdin - GuruFocus.com |
- Analyzing TC BioPharm's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether TC BioPharm's stock is overvalued or undervalued compared to its peers.
- Examining TC BioPharm's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating TC BioPharm's management team can have a significant impact on its success or failure. Reviewing the track record and experience of TC BioPharm's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of TC BioPharm's stock. These opinions can provide insight into TC BioPharm's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for TCBPW Stock Analysis
When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.